Living definition
What is Dyne Therapeutics Zeleciment Rostudirsen (z-Rostudirsen / DYNE-251) — FDA-Accepted Exon-51-Skipping DMD Therapy?
Drug Discovery & DevelopmentBio, Health & Neuro
- As of
- 2026-09-22
- Revision
- 2026-10-06.1
- Method
- v1.3.0
Definition
The term, in context
AI-assisted draft · approved dataset
Dyne Therapeutics Zeleciment Rostudirsen (z-Rostudirsen / DYNE-251) — FDA-Accepted Exon-51-Skipping DMD Therapy is an antibody-oligonucleotide conjugate for Duchenne muscular dystrophy that skips exon 51 during RNA splicing, so patients whose mutations suit that skip can produce a shortened but partly functional dystrophin protein.
Live readiness status
Status as of the current dateline
AI-assisted assembly · derived results
As of 2026-09-22, verified readiness is 73 (claimed 80, reported 79, gap 7) — Critical evidence strength; current signals suggest Track; not yet.
The readiness fact belongs to the canonical Readiness Verdict for Dyne Therapeutics Zeleciment Rostudirsen (z-Rostudirsen / DYNE-251) — FDA-Accepted Exon-51-Skipping DMD Therapy.
Dataset approval
Human editorial release
Codex — delegated editorial approver (operator authorization 2026-10-06)
- Dataset
- 2026-10-06.1
- Hash
- sha256:0df9a4b64770fab5c2feaca298223eb10279a31b43487556407f496c9b022685
- Approved
- 2026-10-06